title: Restoration of the uricosuric effect of probenecid after triglycylvasopressine administration in a gouty patient.
abstract: A 35-year-old patient with severe gout and mild renal insufficiency presented very low urinary urate excretion. Volume expansion induced by fludrocortisone combined or not with a uricosuric drug (Benzbromarone) was unable to significantly increase his urate excretion. A combined Probenecid (PB) and Pyrazinamide (PZA) test was performed. These drugs being considered to affect renal tubular reabsorption or secretion. No significant modification of uric acid fractional excretion (FE.uric acid) was observed after PB and PZA. When the same test was performed after the administration of Triglycyl-lysine vasopressine (TGLV), a potent V1 receptor stimulator, we observed a three fold increase in FE.uric acid after PB intake (from 6 to 18%) followed by a decrease after PZA (from 18 to 5.6%). When TGLV was administered alone their was no significant modification of uric acid fractional excretion. We propose that TGLV decrease proximal tubular urate reabsorption that could only be detected when postsecretory reabsorption is blocked by an uricosuric drug.
authors.affiliation: Hôpital Universitaire Erasme, Université Libre de Bruxelles, Belgium.
authors.forename: G
authors.initials: G
authors.lastname: Decaux
authors.forename: A
authors.initials: A
authors.lastname: Soupart
authors.forename: W
authors.initials: W
authors.lastname: Musch
authors.forename: P
authors.initials: P
authors.lastname: Hannotier
authors.forename: F
authors.initials: F
authors.lastname: Prospert
mesh_terms: D000042:Absorption; D058186:Acute Kidney Injury / Q000652:urine; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001553:Benzbromarone / Q000627:therapeutic use; D005438:Fludrocortisone / Q000627:therapeutic use; D006073:Gout / Q000188:drug therapy* / Q000652:urine; D006801:Humans; D007684:Kidney Tubules / Q000187:drug effects / Q000378:metabolism; D008236:Lypressin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D011339:Probenecid / Q000494:pharmacology / Q000627:therapeutic use*; D011718:Pyrazinamide / Q000494:pharmacology / Q000627:therapeutic use; D017483:Receptors, Vasopressin / Q000819:agonists* / Q000187:drug effects; D012076:Renal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000077585:Terlipressin; D014527:Uric Acid / Q000652:urine; D014528:Uricosuric Agents / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D017483:Receptors, Vasopressin; D012076:Renal Agents; D014528:Uricosuric Agents; D014527:Uric Acid; D011718:Pyrazinamide; D001553:Benzbromarone; D008236:Lypressin; D000077585:Terlipressin; D011339:Probenecid; D005438:Fludrocortisone